SRPT vs. ANF

The year-to-date returns for both stocks are quite close, with SRPT having a -51.80% return and ANF slightly lower at -52.99%. Both investments have delivered pretty close results over the past 10 years, with SRPT having a 14.85% annualized return and ANF not far behind at 14.62%.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Sarepta Therapeutics, Inc. (SRPT) and Abercrombie & Fitch Co. (ANF). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current SRPT Sharpe Ratio is -0.93, which is comparable to the ANF Sharpe Ratio of -0.75. The chart below compares the historical Sharpe Ratios of SRPT and ANF, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither SRPT nor ANF has paid dividends to shareholders.

The maximum SRPT drawdown since its inception was -98.17%, which is greater than ANF's maximum drawdown of -86.59%. Use the drawdown chart below to compare losses from any high point for SRPT and ANF. For additional features, visit the drawdowns tool.

Sarepta Therapeutics, Inc. (SRPT) has a higher volatility of 35.73% compared to Abercrombie & Fitch Co. (ANF) at 23.77%. This indicates that SRPT's price experiences larger fluctuations and is considered to be riskier than ANF based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Sarepta Therapeutics, Inc. and Abercrombie & Fitch Co.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.